Susceptibility to the combination treatment with cobimetinib and idasanutlin was present in AML cells defined by normal karyotype (NK) and wild type status of the TP53 gene with elevated FLT3 and MDM2 protein levels. The gene discussed is MDM2; the disease is acute myeloid leukemia.